Arsenic Trioxide in Patients with Hepatocellular Carcinoma: a Phase II Trial

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2006 Aug 29

PMID 16937079

Citations 46

Authors

Chia-Chi Lin

Chiun Hsu

Chih-Hung Hsu

Wei-Ling Hsu

Ann-Lii Cheng

Chih-Hsin Yang

Affiliations

Soon will be listed here.

Abstract

Background: Arsenic trioxide induces growth inhibition and apoptosis in human hepatocellular carcinoma (HCC) cell lines. A phase II trial was conducted to evaluate the efficacy and toxicity of single-agent arsenic trioxide in patients with HCC.

Methods: Inclusion criteria included advanced HCC patients to whom no standard palliative treatment can be offered, good organ function and liver function reserve. Patients received arsenic trioxide 0.16-0.24 mg/kg per day for 5-6 days per week for 3-4 weeks, followed by one-week rest. Tumor response was assessed every 2 cycles. Primary endpoint was the percentage of patients with 6-month disease stabilization.

Results: Twenty-nine patients (median age, 59) with locally advanced or metastatic HCC received a total of 61 cycles (median, 2; range, 1-6). One patient had partial response. Three patients had disease stabilization for at least six months. The 6-month tumor stabilization rate was 14% (95% CI, 1-27). The median overall survival was 4.8 months (95% CI, 1.4-8.2) and one-year survival was 30%.

Conclusion: Single-agent arsenic trioxide using this dose schedule is not active against advanced HCC.

Citing Articles

A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine.

He H, Dumesny C, Carrall J, Dillon C, de Roo K, Eutick M Int J Mol Sci. 2024; 25(21).

PMID: 39518921 PMC: 11546692. DOI: 10.3390/ijms252111366.

Multiple roles of arsenic compounds in phase separation and membraneless organelles formation determine their therapeutic efficacy in tumors.

Qu M, He Q, Bao H, Ji X, Shen T, Barkat M J Pharm Anal. 2024; 14(8):100957.

PMID: 39253293 PMC: 11381784. DOI: 10.1016/j.jpha.2024.02.011.

Valence-Change MnO-Coated Arsenene Nanosheets as a Pin1 Inhibitor for Hepatocellular Carcinoma Treatment.

Wang J, Liang S, Zhu D, Ma X, Peng Q, Wang G J Am Chem Soc. 2024; 146(31):21568-21582.

PMID: 39051165 PMC: 11311233. DOI: 10.1021/jacs.4c05162.

Arsenic Trioxide Suppresses Angiogenesis in Non-small Cell Lung Cancer the Nrf2-IL-33 Signaling Pathway.

Wang M, Yin J, Han Q, Li B, Zhao X, Xue L Anticancer Agents Med Chem. 2024; 24(15):1142-1150.

PMID: 38847245 DOI: 10.2174/0118715206288348240420174853.

Arsenic trioxide impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection.

Hofmann S, Luther J, Plank V, Oswald A, Mai J, Simons I Microbiol Spectr. 2024; 12(5):e0378823.

PMID: 38567974 PMC: 11064512. DOI: 10.1128/spectrum.03788-23.

References

Niu C, Yan H, Yu T, Sun H, Liu J, Li X . Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94(10):3315-24. View

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

Barbare J, Bouche O, Bonnetain F, Raoul J, Rougier P, Abergel A . Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005; 23(19):4338-46. DOI: 10.1200/JCO.2005.05.470. View

Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C . Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood. 2003; 102(3):1028-34. DOI: 10.1182/blood-2002-04-1154. View

Vuky J, Yu R, Schwartz L, Motzer R . Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs. 2002; 20(3):327-30. DOI: 10.1023/a:1016270206374. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Barbey J, Pezzullo J, Soignet S . Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003; 21(19):3609-15. DOI: 10.1200/JCO.2003.10.009. View

Roboz G, Dias S, Lam G, Lane W, Soignet S, Warrell Jr R . Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000; 96(4):1525-30. View

Zhang T, Wang S, Hong L, Wang X, Qi Q . Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo. J Exp Clin Cancer Res. 2003; 22(1):61-8. View

10.

. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28(3):751-5. DOI: 10.1002/hep.510280322. View

11.

Yeo W, Mok T, Zee B, Leung T, Lai P, Lau W . A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97(20):1532-8. DOI: 10.1093/jnci/dji315. View

12.

Liaw Y, Tai D, Chen T, Chu C, Huang M . Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver. 1986; 6(3):133-7. DOI: 10.1111/j.1600-0676.1986.tb00279.x. View

13.

Soignet S, Maslak P, Wang Z, Jhanwar S, Calleja E, Dardashti L . Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998; 339(19):1341-8. DOI: 10.1056/NEJM199811053391901. View

14.

Hsu C, Chen C, Chen L, Wu C, Yang P, Lai M . Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology. 2003; 65(3):242-9. DOI: 10.1159/000074477. View

15.

Okuda K . Early recognition of hepatocellular carcinoma. Hepatology. 1986; 6(4):729-38. DOI: 10.1002/hep.1840060432. View

16.

Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View

17.

Dai J, Weinberg R, Waxman S, Jing Y . Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1998; 93(1):268-77. View

18.

Leung T, Tang A, Zee B, Yu S, Lai P, Lau W . Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002; 94(2):421-7. DOI: 10.1002/cncr.10236. View

19.

Douer D, Tallman M . Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005; 23(10):2396-410. DOI: 10.1200/JCO.2005.10.217. View

20.

Shao W, Fanelli M, Ferrara F, Riccioni R, Rosenauer A, DAVISON K . Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 1998; 90(2):124-33. DOI: 10.1093/jnci/90.2.124. View